For independent finance newsletter & Substack writers
The EDGAR legwork done, every Monday — you still write the piece
A weekly packet of Graham/Buffett-style value-investing research — a whole-market quality-and-cheapness screen plus per-name metrics and EDGAR filing excerpts — licensed for you to adapt and republish under your own byline. Built for independent finance newsletter and Substack writers who don't want to spend 1-2 weeks per piece doing the screening and filing legwork themselves. $49/mo, no contract.
Licensed for your own byline
Every subscription includes a non-exclusive license to adapt and republish material from the weekly packet in your own commercially published newsletter or blog, under your own name. This is a research input for you to build on, not a ghostwritten article — you're expected to add your own framing, voice, and conclusions.
First packet lands the Monday after you sign up. Sample below uses a real run of the underlying screen and filing pulls — no invented numbers.
Sample weekly packet
Every week the packet includes a whole-market quality screen (ROE ≥ 12%, positive earnings over 8-10 years, sound balance sheet, ≥ $2B market cap, ranked cheapest-first by margin of safety), then a per-name metrics table and filing excerpt for the names worth a closer look. Below is an actual run against two names from a recent screen.
Per-name Graham metrics
| Ticker | Price | P/E | P/B | Graham $ | Margin of safety | ROE | Current ratio | D/E | Yield | EPS+ yrs |
|---|---|---|---|---|---|---|---|---|---|---|
| LDOS | $128.86 | 11.57 | 3.31 | $98.74 | -23.4% | 29.5% | 1.70 | 1.74 | 1.3% | 10/10 |
| CTSH | $60.00 | 13.16 | 1.91 | $56.76 | -5.4% | 14.9% | 2.14 | 0.38 | 2.1% | 9/10 |
Margin of safety vs. Graham fair value (negative = trading above fair value at the time of this run). Both names cleared the quality bar but were trading rich to Graham fair value when this sample was pulled — that's reported as-is, not filtered out.
Filing excerpt — LDOS (Leidos Holdings)
From the latest 10-K, risk factors (filed 2026-02-17): Leidos depends on U.S. government agencies as its primary customers; a decline in government budgets, delays in the appropriations process, contract terminations, bid protests, and organizational-conflict-of-interest rules are all called out as risks that could affect future revenue and growth.
From the latest 10-Q (filed 2026-08-04, quarter ended July 3, 2026): Revenue $4,558M vs. $4,394M in the year-ago quarter; net income $355M vs. $390M; diluted EPS $2.80 vs. $2.98. The quarter includes acquisition, integration, and restructuring costs of roughly $30M tied to a recent acquisition.
Source: SEC EDGAR filings for Leidos Holdings, Inc. (CIK 1336920). This is a raw excerpt, not a recommendation — build your own analysis and conclusions on top of it.
Frequently asked
Who is this for?
Independent finance newsletter and Substack writers who publish their own value-investing commentary and want raw research inputs — not finished prose. If you already write your own stock write-ups but the EDGAR pulls, screening, and ratio math eat most of your week, this is the part you're outsourcing.
Can I actually republish this under my own name?
Yes. Your subscription includes a non-exclusive license to adapt, rewrite, and publish material derived from the weekly packet in your own commercially published newsletter or blog, under your own byline. You're buying research inputs to build your own piece on top of, not a finished article to paste in verbatim — most subscribers rewrite the framing and add their own voice and conclusions before publishing.
How is this different from a done-for-you newsletter service?
Services like Potions or NewsletterAsAService ($250-1,500/mo) write finished commentary for you, but they explicitly exclude long-form original research from what they'll do — someone still has to do the screening and filing work. ValueFeed is that missing input: the screen, the metrics, the filing excerpts. You still write the actual piece.
How is this different from AdvisorLetter, Edge Thirteen's other subscription?
AdvisorLetter sells financial advisors a finished, ready-to-forward commentary draft for client communications. ValueFeed sells independent research writers raw structured data and analysis — company screens, Graham metrics, filing excerpts — for them to turn into their own original commentary. Different customer, different product: finished prose vs. raw research.
Where does the data come from?
SEC EDGAR filings (10-Ks, 10-Qs) and standard Graham/Buffett quality-and-value screening criteria (return on equity, earnings consistency, balance-sheet strength, valuation vs. intrinsic value). Every number in the weekly packet traces back to an actual filing or an actual screen run — nothing is estimated or invented.
Is this investment advice?
No. It's research data and analysis for you, a publisher, to use as raw material for your own independent commentary. You're responsible for your own editorial judgment and any disclosures your own publication requires.
Can I cancel any time?
Yes, it's a monthly Stripe subscription with no contract.